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Estradiol upregulates calcineurin expression via
overexpression of estrogen receptor alpha gene in
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doi:10.1016/j.kjms.2010.12.005Abstract Systemic lupus erythematosus (SLE) is an autoimmune disease primarily affecting
women (9:1 compared with men). To investigate the influence of female sex hormone estrogen
on the development of female-biased lupus, we compared the expression of estrogen receptor
alpha (ERa) gene and protein levels as well as expression of T-cell activation gene calcineurin
in response to estrogen in peripheral blood lymphocytes (PBLs) from SLE patients and normal
controls. PBLs were isolated from 20 female SLE patients and 6 normal female controls. The
amount of ERa protein in PBL was measured by flow cytometry. The expression of ERa and cal-
cineurin messenger RNA was measured by semi-quantitative reverse transcription-polymerase
chain reaction. Calcineurin phosphatase activity was measured by calcineurin assay kit. The
expression of ERa messenger RNA and ERa protein was significantly increased (pZ 0.001 and
pZ 0.023, respectively) in PBL from SLE patients compared with that from normal controls.Allergy, Immunology, and Rheumatology, Department of Medicine, Kaohsiung Medical University
y, 100 Zihyou 1st Road, Kaohsiung 807, Taiwan.
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雌激素受體a基因;
全身性紅斑狼瘡In addition, the basal calcineurin in PBL from SLE patients was significantly higher (pZ 0.000)
than that from normal controls, and estrogen-induced expression of calcineurin was increased
(pZ 0.007) in PBL from SLE patients compared with that from normal controls, a 3.15-fold
increase. This increase was inhibited by the ERa antagonism ICI 182,780. The effects of ER
antagonism were also found in calcineurin activity. These data suggest that overexpression
of ERa gene and enhanced activation of calcineurin in response to estrogen in PBL may
contribute to the pathogenesis of female dominant in SLE.
摘要 全身性紅斑狼瘡是一種自體免疫疾病，主要侵犯女性為主 (男女比為 1:9)。為探討女性雌
激素如何影响紅斑狼瘡偏向女性發生而研究狼瘡病人與正常人週邊血液淋巴球之雌激素受體a 基
因與蛋白的表現。我們收集了20 位女性之紅斑狼瘡病人與6位正常女性志願者為研究對象。雌激
素受體a蛋白的表現是以流式細胞測定儀定量之。雌激素受體a 和蛋白質磷酸酶 3CA 信息核醣核
酸之測定是以半定量之逆轉錄鏈聚合反應測定之。蛋白質磷酸酶 3CA 之活度是以蛋白質磷酸酶
分析用成套工具測定之。結果發現紅斑狼瘡周邊血淋巴球雌激素受體a之信息核醣核酸及蛋白的
表現比正常人有意義增加，其 p 值分別為 0.001和 0.023。此外基礎之蛋白質磷酸酶 3CA 表現在
紅斑狼瘡淋巴球比正常人有意義的增加，p 值Z0.000。雌激素誘發之蛋白質磷酸酶 3CA 表現在
紅斑狼瘡淋巴球比正常人有意義的增加 (pZ0.007), 其增加為 3.15 倍, 此增加可被雌激素受體拮
抗者ICI 182,780 抑制。雌激素受體拮抗現象亦發生於蛋白質磷酸酶 3CA 之磷酸酶活度。由以上
結果顯示雌激素受體 a 基因的過度表現以及淋巴球因雌激素之刺激所導致蛋白質磷酸酶 3CA 之
高度活化結果對狼瘡病人之偏向女性之致病機轉有所貢獻。
Copyright ª 2011, Elsevier Taiwan LLC. All rights reserved.Introduction
Women have a higher incidence of autoimmune disorders,
such as systemic lupus erythematosus (SLE) and rheumatoid
arthritis [1], but the mechanism for this higher incidence is
still unknown. Multiple mechanisms may contribute to the
female bias in autoimmune diseases [2]. Several lines of
evidence have indicated that sex hormone estrogens or
their metabolites contribute to the female predilection or
to exacerbation of SLE [3e6]. Estrogen functions as a tran-
scriptional regulator by activating estrogen receptors (ERs),
estrogen receptor alpha (ERa), and estrogen receptor beta
(ERb), which then translocate to the nucleus, where they
bind to estrogen response elements in gene promoters.
Although both ERs are expressed in most immune cells, ERa
is shown to be predominantly expressed [1]. Results from
human studies indicate that estrogens enhance lupus
development, but concrete evidence implicating the ER in
promoting SLE is lacking. Recent murine studies using ER-
selective agonists in New Zealand Black New Zealand
White F1 female mice have suggested that activation of
ERa, but not ERb, promotes SLE [2]. On the contrary, ER-
deficient New Zealand Black New Zealand White F1 and
NZM2419 mice with disruption of ERa attenuate glomeru-
lonephritis and increase survival [7,8]. One of these studies
has further indicated that ERa promotes lupus by inducing
interferon-gamma, an estrogen-regulated cytokine that
impacts this disease [8]. These data suggest that ERa plays
a major role in mediating the effects of endogenous
estrogens by promoting both loss of tolerance and the
development of pathogenic autoantibodies [8]; however,
studies of ERa in mediating estrogen’s effect on human SLE
are limited. Although the peripheral blood mononuclear
cells (PBMCs) of SLE patients have been reported to express
wild-type ERa and ERb like those of normal individuals
[9,10], a recent report observed that expression of ERa,
but not ERb, was increased in PBMC from SLE patientscompared with normal controls [11]. These conflicting
results prompted us to perform a quantitative analysis of
ERa gene as well as protein expression by peripheral blood
lymphocytes (PBLs) from SLE patients and a comparison
with normal controls.Materials and methods
Human subjects and cell culture
Approval for this study was obtained from Kaohsiung
Medical University Hospital Human Ethics Committee.
Twenty female patients with SLE and six healthy female
controls were recruited in this study. The lupus patients
were between 19 and 48 years of age [mean standard
deviation (SD)Z38.2 8.73 years]. All had regular
menstrual cycle. They were selected randomly from
outpatient services and met the American College of
Rheumatology criteria for classification of SLE [12]. Disease
duration varied from 4 years to 25 years with a mean SD
of 12.2 6.29 years. Most of our patients were in remission
state, their disease activity varying from none to active
with SLE disease activity index scores of between 0 and 11
(mean 4.89 3.48). Four patients were not taking pred-
nisolone. Two patients were receiving prednisolone at
doses of 35 mg/d and 20 mg/d, respectively. Two patients
were receiving 7.5 mg/d. The other 12 patients were
receiving 5 mg/d. Nineteen patients were on hydroxy-
chloquine (100e200 mg/d), one was on cyclophosphamide
50 mg/d and none were on azathiopurine. The female
controls were six healthy volunteers selected from the
laboratory staff aged between 25 and 35 years (mean
33.3 1.37 years) with normal menstrual cycle and no
history of collagen vascular disease. PBMCs were isolated by
using Ficoll-Paque cushion centrifugation gradient. Cells
were harvested and cultured in petri dishes for 2 hours.
Overexpression of ERa gene in SLE 127Nonadherent cells (lymphocyte-rich cells; PBL) were har-
vested and cultured in RPMI-1640 medium supplemented
with 10% fetal bovine serum (Biological Industries, Beit
Haemek, Israel) until use. Estradiol (Sigma Chemical Co.,
St. Louis, MO, USA) at the concentration of 0.2 mg/mL was
used to measure dose-dependent response. ER antagonist
ICI 182,780 (Sigma Chemical Co) at the concentration of
4 mg/mL was used in ERa antagonism.
Flow cytometry analysis
Immunostaining of ERa was performed as described previ-
ously with modification [13]. Harvested cells were first
fixed in 4% paraformaldehyde in phosphate-buffered saline
(PBS) for 30 minutes on ice followed by washing and
resuspension in PBS, and then they were permeabilized
with 0.1% Triton X-100 at 4C for 5 minutes. Cells were
stained with rabbit anti-human ERa antibody (Upstate
Biotechnology, Charlotteswille, VA, USA) for 30 minutes
and goat anti-rabbit IgG antibody-conjugated fluorescein
isothiocyanate (Santa Cruz Biotechnology, Santa Cruz, CA,
USA) for 30 minutes followed by washing and resuspension
in PBS. The positive cell count and the mean fluorescent
intensity were analyzed by Coulter Epics XL Flow Cytom-
eter (Beckman Coulter, Ramsey, MN, USA). The data were
processed using EXPO32 ADC Software (Beckman Coulter,
Ramsey, MN, USA).
Semi-quantitative reverse transcription-
polymerase chain reaction
Cells were cultured with or without estradiol for 24 hours.
Total RNA was extracted using REzol TM C & T (Promega,
Madison, WI, USA) according to the manufacturer’s
instructions. Reverse transcription (RT) was performed
with 1 mg RNA, 20 mL of reaction reagent containing 5 mM
MgCl2, 1 mM dNTP mixture, 62.5 U RNase inhibitor, 0.5 mg
oligo(dT)15 primer, and 15 U avian myeloblastosis virus
reverse transcriptase in RT buffer [10 mM TriseHCl (pH 9.0
at 25C), 50 mM KCl, and 0.1% Triton X-100]. The mixture
was incubated at 42C for 15 minutes, followed by 99C for
5 minutes and 4C for 5 minutes. After RT, 0.625 U Taq DNA
polymerase, 1.5 mMMgCl2, 0.8 mM dNTP, and 50 pM of each
primer in polymerase chain reaction (PCR) buffer were
added to the complementary DNA mixture, the volume
being 50 mL. After denaturation at 95C for 5 minutes, 30
cycles of b-actin amplification were performed at 94C for
45 seconds, 60C for 45 seconds, and 72C for 1.5 minutes/
cycle; ERa, at 94C for 45 seconds, 50C for 45 seconds, and
72C for 1.5 minutes/cycle. The primers for b-actin
message amplification were (forward) 50-ATC TGG CAC CAC
ACC TTC TAC AAT GAG CTG CG-30 and (reverse) 50-CGT CAT
ACT CCT GCT TGC TGA TCC ACA TAT GC-30; ERa were
(forward) 50-TGC CAA GGA GAC TCG CTA CT-30 (904e923)
and (reverse) 50-CTG GCG CTT GTG TTT CAA C-30
(1180e1162); calcineurin were (forward) 50-TTG ATT GCC
ACT GTA GTT TGG T-30(2888e2909) and (reverse) 50-CAG
CGG CCC ATG CAT GGA AAT TT-30. The PCR products of
b-actin, ERa, and calcineurin were electrophoresed on
a 2% agarose minigel at 100 V for 30 minutes and visualized
with ethidium bromide staining under UV illumination.Multimers of 100-bp DNA ladder plus were used as makers
(MBI Fermentas, Hanover, MD, USA). The density of the
bands was measured by densitometry, and the background
was subtracted; subsequently, the ratios of ERa and cal-
cineurin to b-actin mRNA were calculated, respectively.
Calcineurin phosphatase activity assay
Calcineurin enzymatic activity was measured using a calci-
neurin assay kit (Biomol, Polymouth Meeting, PA, USA). The
activity was measured as the phosphorylation rate of
a synthetic phosphopeptite substrate (RII pt peptite) with
the Biomol Green reagent and read optical density 620 nm
on a microplate reader.
ERa antagonism
PBLs from lupus patients were cultured for 24 hours in
medium alone, medium plus estradiol (0.2 mg/mL), medium
plus ER antagonist ICI 182,780 (4 mg/mL), and medium plus
estradiol (0.2 mg/mL) and ICI 182,780 (4 mg/mL). Total RNA
was isolated, and calcineurin mRNA was measured using
semi-quantitative RT-PCR. Calcineurin phosphatase activity
was measured by calcineurin assay kit in cells using the same
culture condition.
Statistical analysis
Data were expressed as the mean SD and mean standard
error of the mean. Comparisons of numerical data between
groups were performed by Student t test. Values of p< 0.05
were considered statistically significant.
Results
ERa gene expression was upregulated in PBL from
SLE patients
To investigate if the expression of the ERa gene was upre-
gulated in patients with SLE, we analyzed PBL from patients
with SLE and healthy controls using semi-quantitative
RT-PCR. For internal control of the RNA, the expression of
b-actin was also examined and the amount of ERa gene was
normalized to the endogenous reference b-actin. The
normalized ER-a gene expression (^Cr) of SLE patients was
then related to the ^Cr of healthy controls for their relative
expression levels. The results showed that the expression of
ERa gene in SLE patients was significantly higher (p< 0.001)
compared with that in healthy controls (Fig. 1). These
observations indicate that ERa gene expression is upregu-
lated in patients with SLE.
ERa protein was also upregulated in PBL from SLE
We further investigated the ERa protein expression using
flow cytometry. As shown in Fig. 2, the ERa protein
expression in SLE was significantly increased (pZ 0.023)
compared with that in healthy controls. These results
confirmed the observation obtained from semi-quantitative
RT-PCR that ERa was indeed upregulated in SLE.
Figure 1. ERa mRNA in peripheral blood lymphocyte of
SLE patients is increased compared with normal controls.
(A) Representative experiments showing the ERa and b-actin
mRNA levels in PBL from three normal controls and three SLE
patients. (B) The results are mean  standard deviation of ERa
to b-actin mRNA ratio (*pZ 0.001). ERaZ estrogen receptor
alpha; SLEZ systemic lupus erythematosus.
Figure 2. Intracellular ERa protein expression in peripheral
blood lymphocyte of SLE patients is increased compared with
normal controls. (A) Representative histograms of ERa are
shown. The percentage displays the results of ERa-positive
cells. (B) Statistical histograms of ERa. Data are mean
standard deviation percentage of ERa-positive cells
(*pZ 0.023). ERaZ estrogen receptor alpha; SLEZ systemic
lupus erythematosus.
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The concentration of estradiol in the plasma of normal
women is less than 0.5 mg/mL (<2 nM). In most studies,
estradiol has been used in concentrations (micromolar
levels) hundreds of fold higher than normal plasma level
[14,15]. To investigate the concentrations of estradiol that
increase calcineurin expression, we cultured PBL from lupus
patients without estradiol and in medium containing
estradiol of 0.2, 2.0, and 20 mg/mL for 24 hours. The mean
calcineurin expression in SLE cells cultured at concentration
of 0.2, 2.0, and 20 mg/mL of estradiol was 0.487, 0.407, and
0.417, respectively (Fig. 3). Hence, estradiol concentration
at 0.2 mg/mL was used to measure the expression of calci-
neurin in response to estrogen.
Estradiol increased calcineurin and phosphatase
activity in PBL from SLE patients
We have shown previously that ERa mRNA expression and
protein level are increased in lupus patients compared with
normal controls. However, how overexpressed ERamediates
the female sex hormone estrogen is unknown. In this study,
we showed that the basal levels of calcineurin expression
were significantly increased (pZ 0.000) in PBL from SLE
patients compared with PBL from normal controls. The
increase was 4.03-fold. When estradiol was added to
cultures, the calcineurin expression from normal controls
was not increased significantly (pZ 0.103) while that fromSLE patients increased significantly (pZ 0.017). The calci-
neurin in SLE was 3.15-fold higher than in normal controls
(Fig. 4). Similar effects were found in phosphatase activity
of the protein that exerts biological effects (Fig. 5). Varia-
tion of phosphatase activity was not prominent in cells of
normal controls cultured with and without estradiol,
whereas the phosphatase activity in PBL of lupus patients
cultured with estradiol increased significantly (pZ 0.005)
compared with that cultured without estradiol. This
increase was inhibited by the ER antagonist ICI 182,780.
Taken together, these data indicate that the increase of
calcineurin expression in response to estrogen appeared to
be limited to lupus patients.
ERa mediates the estradiol-dependent increase in
calcineurin mRNA
To investigate if the estrogen-dependent increase in calci-
neurin was mediated by the ERa, PBLs from lupus patients
were cultured in medium alone, medium containing estra-
diol, medium containing ER antagonist ICI 182,780, and
medium containing estradiol plus ICI 182,780 for 24 hours.
Total RNA was isolated, and the expression of calcineurin
mRNA was measured using semi-quantitative RT-PCR. As
shown in Fig. 6, PBL from SLE cultured with estradiol
expressed significantly more calcineurin mRNA compared
with PBL cultured in medium alone, and this increase was
inhibited by the ER antagonist ICI 182,780. Taken together,
βFigure 3. Effect of nonphysiological concentrations of
estradiol on calcineurin gene expression. Total RNA was iso-
lated from PBL of three SLE patients treated for 24 hours with
varying concentrations of E2. The RNA was analyzed by semi-
quantitative reverse transcription-polymerase chain reaction.
Data are mean standard error of the mean of CN to b-actin
mRNA ratios. CNZ calcineurin; E2Z estradiol; mRNAZmes-
senger RNA; PBLZ peripheral blood lymphocyte; SLEZ syste-
mic lupus erythematosus.
Figure 5. Comparison of calcineurin phosphatase activity in
PBLbetweenSLEpatients andnormalcontrols. PBLswere isolated
from SLE patients and normal controls and treatedwith none, E2,
or E2 plus ICI 182,780 (E2þ ICI). Calcineurin activity was
measured using a calcineurin assay kit. Data aremean standard
deviation of phosphatase released (nM) (*pZ 0.001; **pZ 0.005;
#pZ 0.000). E2Z estradiol; PBLZ peripheral blood lymphocyte;
SLEZ systemic lupus erythematosus.
Overexpression of ERa gene in SLE 129these results show that ER antagonist ICI 182,780 inhibited
the estrogen-dependent upregulation of both calcineurin,
indicating that ER directly mediates the action of estradiol
on PBL.Figure 4. Calcineurin mRNA in PBL of SLE patients treated
with and without estradiol compared with normal controls.
Total RNA was isolated from none or E2-treated PBLs that were
prepared from SLE patient and normal controls. The RNA was
analyzed by semi-quantitative reverse transcription-poly-
merase chain reaction. Data are mean standard deviation of
CN to b-actin mRNA ratios (*pZ 0.000; **pZ 0.017;
#pZ 0.007). CNZ calcineurin; E2Z estradiol; mRNAZmes-
senger RNA; PBLZ peripheral blood lymphocyte; SLEZ syste-
mic lupus erythematosus.Discussion
Recent studies have made it clear that activation of ERa but
not ERb, at least in mice, promotes the development of
SLE. However, studies directed toward the role of ERa in
human SLE were limited. In the present study, we examined
the ERa expression levels in SLE patients using semi-quan-
titative RT-PCR and explored its role in SLE. Interestingly,
we found that not only the ERa gene expression was upre-
gulated in cells of SLE patients but also the ERa protein
expression was significantly increased. Our observation is
consistent with a recent study [11], which showed signifi-
cant increased expression of ERa mRNA in PBMC from SLE
patients compared with that from normal controls, but
which did not explore ERa protein level and its role in
mediating estrogen function. Other studies found no
significant difference in the number and affinity of ER
estimated by tritiated-estradiol binding assay and immu-
noblotting between SLE patients and normal controls
[16,17]. There are two possible reasons for this discrep-
ancy: (1) ER is a protein associated with the nucleus, and
staining of ER requires membrane penetration by anti-ER
antibodies and (2) epitopes recognized by some anti-ER
antibodies in a denatured stage suitable for Western blot-
ting may be sterically hindered in intact cells from binding
by anti-ER antibodies [13].
The increase of the ER expression in PBL of SLE patients
could reflect a factor predisposing to the disease, or it
could be a consequence of the disease state. Recent studies
involving various mouse models of lupus have suggested
a prominent role for ERa in the development of lupus
disease [18e22].
Alternatively, it is possible that the high level of ER
expression in PBL of SLE patients could be because of the
components of the lupus environment that are able to
influence ER expression. Nancy and Berrih-Aknin [23] have
shown that activation of normal thymocytes by inflamma-
tory cytokines increases the level of ER expression in
Figure 6. Estrogen receptor alpha mediates the estradiol-dependent increase in calcineurin. Total RNA was isolated from none,
E2, ICI 182,780 (ICI) or E2 plus ICI-treated peripheral blood lymphocytes that were prepared from two patients with systemic lupus
erythematosus. The RNA was analyzed by semi-quantitative reverse transcription-polymerase chain reaction. Representative
experiments showing the CN and b-actin mRNA levels are shown on the top. The ratio of CN/b-actin mRNA is shown on the bottom.
CNZ calcineurin; E2Z estradiol; mRNAZmessenger RNA.
130 H.-L. Lin et al.thymocytes especially CD4þ subset in vitro, suggesting that
an excess of proinflammatory cytokines could increase the
expression of ERs on myasthenia gravis lymphocytes;
however, data of ERa expression in PBL by inflammatory
cytokines were lacking. This problem is under investigation
in our laboratory. Although murine models of lupus have
suggested a prominent role for ERa in the development of
lupus disease, studies of ERa in mediating estrogen’s
effects on human SLE are limited. Rider and colleagues
[17,24] in previous studies found increased expression of
activation genes calcineurin in SLE T cells cultured in
medium containing ERa agonist but did not demonstrate
a higher amount of ERa in the SLE T cells compared with
normal T cells. They hypothesized that the absence of
either ERa or ERb subtype mRNA cannot account for the
differential action of estrogen in women with lupus. These
findings contradicted those of our study and others [11],
which showed a higher expression of ERa mRNA and lower
expression of ERb mRNA by PBMC from SLE patients
compared with that from normal controls. In the present
study, we observed a significantly higher expression of ERa
gene and protein level in SLE patients than in normal
controls. In addition, we observed that ERa mediates the
estradiol-dependent increase in calcineurin. Such high
expression of ERa may promote the influence of estrogen
on PBL in lupus patients.
The pathogenesis of upregulation of ERa gene in lupus
patients remains unclear. We hypothesize that genetic
susceptibility and an environmental (epigenetic) trigger are
two responsible contributory factors. Numerous studies, to
the best of our knowledge, suggest that genetic factors have
little influence on this female predilection [25e29]. Our
other study intriguingly found that unmethylation in prox-
imal promoter region of ERa gene enhanced ERa expression
in SLE (prepare for submission), suggesting that an epige-
netic factor is associated with upregulation of ERa gene in
SLE. A recent study has indicated that female sex hormone
and male sex hormone through ERa and androgen receptor
differentially regulate the expression of the interferon-
inducible lupus susceptibility (Ifi202) gene in immune cells,
and female sex hormone-dependent increased levels of p202protein in B cells by increasing cell survival contribute to sex
bias in lupus susceptibility [6]. Evidence for the role of
estrogen and progesterone in sex differences of SLE are
derived from murine models although these hormone levels
are normal in most SLE patients of either sex [30]. Clinical
research provides support for a more estrogenic environ-
ment in patients with SLE of both sexes. A preferential
hydroxylation of estrone and increased oxidation of testos-
terone in patients with SLE maximize the effects of estro-
gens on T-cell functions [31]. Although these changes are
found in males and females, they are most marked in
females. These findings and the present work suggest that
female sex hormone estrogen plays a key role in contributing
to female sex bias in lupus susceptibility through increased
expression of ERa.
In conclusion, our study indicates that ERa gene was
upregulated in SLE patients. This overexpressed ERa in turn
mediates the female sex hormone estrogen and evokes
a direct increase in calcineurin expression in PBL, which
could at least in part contribute to female bias in the
development of SLE.
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